CNR1 and autism spectrum disorder: CB1R/CB2R activation ameliorates behavioral deficits and rectifies hippocampal lipid dysregulation in a VPA‐induced ASD rat model, highlighting the endocannabinoid system's therapeutic potential for autism spectrum disorders.